Prevention Familial hypercholesterolaemia in children and adolescents : gaining decades of life by optimizing detection and treatment

Albert Wiegman1†*, Samuel S. Gidding2†, Gerald F. Watts3, M. John Chapman4,5, Henry N. Ginsberg6,7, Marina Cuchel8, Leiv Ose9,10, Maurizio Averna11, Catherine Boileau12,13,14, Jan Borén15,16, Eric Bruckert17, Alberico L. Catapano18,19, Joep C. Defesche20, Olivier S. Descamps21, Robert A. Hegele22, G. Kees Hovingh20, Steve E. Humphries23, Petri T. Kovanen24, Jan Albert Kuivenhoven25, Luis Masana26,

[1]  D. Gaudet,et al.  The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial. , 2015, Atherosclerosis.

[2]  E. Sijbrands,et al.  Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. , 2015, European heart journal.

[3]  J. Hay,et al.  Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States. , 2015, International journal of cardiology.

[4]  David M. Herrington,et al.  Multiple rare alleles at LDLR and APOA5 confer risk for early-onset myocardial infarction , 2014, Nature.

[5]  Michael J. Pencina,et al.  Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease , 2015, Circulation.

[6]  F. Raal,et al.  Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial , 2015, The Lancet.

[7]  J. Borén,et al.  [Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society]. , 2015, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[8]  S. Humphries,et al.  Statins for children with familial hypercholesterolemia. , 2020, The Cochrane database of systematic reviews.

[9]  Andrew B. Kirke,et al.  Optimising the detection and management of familial hypercholesterolaemia: central role of primary care and its integration with specialist services. , 2014, Heart, lung & circulation.

[10]  Diederik F Van Wijk,et al.  Nonpharmacological lipoprotein apheresis reduces arterial inflammation in familial hypercholesterolemia. , 2014, Journal of the American College of Cardiology.

[11]  J. Kastelein,et al.  Ten-year follow-up after initiation of statin therapy in children with familial hypercholesterolemia. , 2014, JAMA.

[12]  B. Falkner,et al.  A double-blind randomized trial of fish oil to lower triglycerides and improve cardiometabolic risk in adolescents. , 2014, The Journal of pediatrics.

[13]  G. Francis,et al.  Effect of rosuvastatin therapy on carotid intima media thickness in children with familial hypercholesterolemia: Findings from the charon study , 2014 .

[14]  P. Iversen,et al.  Markers of atherosclerotic development in children with familial hypercholesterolemia: a literature review. , 2014, Atherosclerosis.

[15]  Z. Ademi,et al.  Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia. , 2014, Journal of clinical lipidology.

[16]  Jennifer G. Robinson,et al.  Curing atherosclerosis should be the next major cardiovascular prevention goal. , 2014, Journal of the American College of Cardiology.

[17]  B. Hansel,et al.  Premature atherosclerosis is not systematic in phytosterolemic patients: severe hypercholesterolemia as a confounding factor in five subjects. , 2014, Atherosclerosis.

[18]  Emily C. O'Brien,et al.  Rationale and design of the familial hypercholesterolemia foundation CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia registry. , 2014, American heart journal.

[19]  J. Kastelein,et al.  Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers. , 2014, Atherosclerosis.

[20]  J. Steinberger,et al.  Implementation of lipid screening guidelines in children by primary pediatric providers. , 2014, The Journal of pediatrics.

[21]  M. Banach,et al.  Management of familial hypercholesterolemia in children and adolescents. Position paper of the Polish Lipid Expert Forum. , 2014, Journal of clinical lipidology.

[22]  A. Tonkin.  Faculty Opinions recommendation of Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. , 2014 .

[23]  S. Yamashita,et al.  Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. , 2014, International journal of cardiology.

[24]  J. Borén,et al.  Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. , 2014, Atherosclerosis.

[25]  Ž. Reiner.  Impact of Early Evidence of Atherosclerotic Changes on Early Treatment in Children With Familial Hypercholesterolemia , 2014, Circulation research.

[26]  F. Raal,et al.  Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9. , 2014, Annual review of medicine.

[27]  J. Kastelein,et al.  Carotid Intima-Media Thickness in Children With Familial Hypercholesterolemia , 2014, Circulation research.

[28]  N. Seidah,et al.  APOE p.Leu167del mutation in familial hypercholesterolemia. , 2013, Atherosclerosis.

[29]  J. Kastelein,et al.  Abstract 17837: Patients With Familial Hypercholesterolemia Who Initiated Statin Treatment In Childhood Are At Lower Risk For Chd Then Their Affected Parents , 2013 .

[30]  Catherine Boileau,et al.  Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease , 2013, European heart journal.

[31]  J. Knowles,et al.  Role of international registries in enhancing the care of familial hypercholesterolaemia. , 2013, International journal of evidence-based healthcare.

[32]  M. Katan,et al.  Trans fatty acids and cardiovascular health: research completed? , 2013, European Journal of Clinical Nutrition.

[33]  Sonia Shah,et al.  Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study , 2013, The Lancet.

[34]  G. Watts,et al.  Familial hypercholesterolaemia in children and adolescents: A new paediatric model of care , 2013, Journal of paediatrics and child health.

[35]  P. Iversen,et al.  Maternal familial hypercholesterolaemia (FH) confers altered haemostatic profile in offspring with and without FH. , 2013, Thrombosis research.

[36]  G. Thompson.  The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular disease. , 2013, Atherosclerosis. Supplements.

[37]  K. Williams,et al.  Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. , 2012, Journal of the American College of Cardiology.

[38]  B. McCrindle.  Familial hypercholesterolemia in children and adolescents , 2012, Current opinion in lipidology.

[39]  S. Gidding,et al.  Universal Screening of Cholesterol in Children , 2012, Clinical cardiology.

[40]  Vincent Plagnol,et al.  Use of targeted exome sequencing as a diagnostic tool for Familial Hypercholesterolaemia , 2012, Journal of Medical Genetics.

[41]  Andrew C. R. Martin,et al.  Low‐Density Lipoprotein Receptor Gene Familial Hypercholesterolemia Variant Database: Update and Pathological Assessment , 2012, Annals of human genetics.

[42]  Z. Ademi,et al.  Familial hypercholesterolaemia: a review with emphasis on evidence for treatment, new models of care and health economic evaluations. , 2012, International journal of evidence-based healthcare.

[43]  S. Gabriel,et al.  Advances in genetics show the need for extending screening strategies for autosomal dominant hypercholesterolaemia. , 2012, European heart journal.

[44]  M. Gagliardi,et al.  Homozygous familial hypercholesterolaemia , 2012, The Lancet.

[45]  J. Kastelein,et al.  Genetic variation in APOB, PCSK9, and ANGPTL3 in carriers of pathogenic autosomal dominant hypercholesterolemic mutations with unexpected low LDL‐Cl Levels , 2012, Human mutation.

[46]  S. Yamashita,et al.  Guidelines for the management of familial hypercholesterolemia. , 2012, Journal of atherosclerosis and thrombosis.

[47]  D. Steinberg.  The Rationale for Initiating Treatment of Hypercholesterolemia in Young Adulthood , 2012, Current Atherosclerosis Reports.

[48]  M. Gautschi,et al.  Fatal myocardial infarction at 4.5 years in a case of homozygous familial hypercholesterolaemia. , 2012, JIMD reports.

[49]  C. Town,et al.  Reduction in Mortality in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in Lipid-Lowering Therapy , 2011, Circulation.

[50]  J. Robinson.  Treatment of Adults with Familial Hypercholesterolemia , 2011 .

[51]  P. Iversen,et al.  Pregnancy Outcomes in Familial Hypercholesterolemia: A Registry-Based Study , 2011, Circulation.

[52]  J. Emery,et al.  Familial hypercholesterolaemia: a model of care for Australasia. , 2011, Atherosclerosis. Supplements.

[53]  C. de Beaufort,et al.  Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. , 2011, Atherosclerosis.

[54]  N. Poulter,et al.  The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K. , 2011, European heart journal.

[55]  C. de Beaufort,et al.  Paediatric screening for hypercholesterolaemia in Europe , 2011, Archives of Disease in Childhood.

[56]  E. Bruckert,et al.  Atheroprotective Reverse Cholesterol Transport Pathway Is Defective in Familial Hypercholesterolemia , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[57]  P. Kolh,et al.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, European heart journal.

[58]  M Thorogood,et al.  Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies , 2011, Heart.

[59]  S. Daniels,et al.  Pediatric aspects of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. , 2011, Journal of clinical lipidology.

[60]  Matthew K. Ito,et al.  Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. , 2011, Journal of clinical lipidology.

[61]  Jennifer G. Robinson,et al.  Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. , 2011, Journal of clinical lipidology.

[62]  Jennifer G. Robinson,et al.  Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. , 2011, Journal of clinical lipidology.

[63]  Jennifer G. Robinson,et al.  Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. , 2011, Journal of clinical lipidology.

[64]  J. Kastelein,et al.  Molecular Basis of Autosomal Dominant Hypercholesterolemia: Assessment in a Large Cohort of Hypercholesterolemic Children , 2011, Circulation.

[65]  C. Vlachopoulos,et al.  Arterial endothelial function and wall thickness in familial hypercholesterolemia and familial combined hyperlipidemia and the effect of statins. A systematic review and meta-analysis. , 2011, Atherosclerosis.

[66]  K. Widhalm,et al.  Sudden death in a 4-year-old boy: a near-complete occlusion of the coronary artery caused by an aggressive low-density lipoprotein receptor mutation (W556R) in homozygous familial hypercholesterolemia. , 2011, The Journal of pediatrics.

[67]  J. Borén,et al.  Lipoprotein(a) as a cardiovascular risk factor: current status , 2010, European heart journal.

[68]  I. Mcdowell,et al.  Integrating provision of specialist lipid services with cascade testing for familial hypercholesterolaemia , 2010, Current opinion in lipidology.

[69]  E. Stroes,et al.  Dilemmas in treatment of women with familial hypercholesterolaemia during pregnancy. , 2010, The Netherlands journal of medicine.

[70]  W. Neal,et al.  Universal Versus Targeted Blood Cholesterol Screening Among Youth: The CARDIAC Project , 2010, Pediatrics.

[71]  R. Latinovic,et al.  Positive screening and carrier results for the England-wide universal newborn sickle cell screening programme by ethnicity and area for 2005–07 , 2010, Journal of Clinical Pathology.

[72]  S. G. Hadfield,et al.  Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project , 2010, Clinical genetics.

[73]  J. Kastelein,et al.  Functionality of sequence variants in the genes coding for the low‐density lipoprotein receptor and apolipoprotein B in individuals with inherited hypercholesterolemia , 2010, Human mutation.

[74]  S. Humphries,et al.  Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia , 2010, Current medical research and opinion.

[75]  P. Hopkins,et al.  Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. , 2010, The Journal of pediatrics.

[76]  J. Kastelein,et al.  Pregnancy in women suffering from familial hypercholesterolemia: a harmful period for both mother and newborn? , 2009, Current opinion in lipidology.

[77]  G. Watts,et al.  Non-adherence to statin therapy: a major challenge for preventive cardiology , 2009, Expert opinion on pharmacotherapy.

[78]  S. Daniels,et al.  Noninvasive assessment of subclinical atherosclerosis in children and adolescents: recommendations for standard assessment for clinical research: a scientific statement from the American Heart Association. , 2009, Hypertension.

[79]  Olli Simell,et al.  COHORT PROFILE Cohort Profile : The STRIP Study ( Special Turku Coronary Risk Factor Intervention Project ) , an Infancy-onset Dietary and Life-style Intervention Trial , 2009 .

[80]  B. Popkin,et al.  Implementing American Heart Association pediatric and adult nutrition guidelines: a scientific statement from the American Heart Association Nutrition Committee of the Council on Nutrition, Physical Activity and Metabolism, Council on Cardiovascular Disease in the Young, Council on Arteriosclerosis, , 2009, Circulation.

[81]  M. Thorogood,et al.  Management of fertility in women with familial hypercholesterolaemia: summary of NICE guidance , 2009, BJOG : an international journal of obstetrics and gynaecology.

[82]  J. Oliva,et al.  [Cost-effectiveness analysis of a genetic screening program in the close relatives of Spanish patients with familial hypercholesterolemia]. , 2009, Revista espanola de cardiologia.

[83]  D. Rader,et al.  Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. , 2008, The American journal of cardiology.

[84]  R. Alonso,et al.  Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors. , 2008, Atherosclerosis.

[85]  S. Humphries,et al.  What is the clinical utility of DNA testing in patients with familial hypercholesterolaemia? , 2008, Current opinion in lipidology.

[86]  S. Humphries,et al.  Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing , 2008, Clinical chemistry and laboratory medicine.

[87]  G. Francis,et al.  Vascular Calcifications in Homozygote Familial Hypercholesterolemia , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[88]  S. Gidding,et al.  Preventing Heart Disease in the 21st Century: Implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Study , 2008, Circulation.

[89]  E. Ros,et al.  Femoral Atherosclerosis In Heterozygous Familial Hypercholesterolemia: Influence Of The Genetic Defect , 2008 .

[90]  K. Widhalm,et al.  Effect of 3-month treatment of children and adolescents with familial and polygenic hypercholesterolaemia with a soya-substituted diet , 2008, British Journal of Nutrition.

[91]  M. Warner.  Child–parent screening for familial hypercholesterolaemia: screening strategy based on a meta-analysis , 2008, Annals of clinical biochemistry.

[92]  K. Berge,et al.  Diagnosis of Familial Hypercholesterolemia in General Practice Using Clinical Diagnostic Criteria or Genetic Testing as Part of Cascade Genetic Screening , 2008, Public Health Genomics.

[93]  T. Graham.  Statin Treatment in Children With Familial Hypercholesterolemia: The Younger, the Better , 2008 .

[94]  J. McEvoy,et al.  Long-term follow-up of the West of Scotland Coronary Prevention Study. , 2008, The New England journal of medicine.

[95]  P. Lázaro,et al.  [Cost-effectiveness of managing familial hypercholesterolemia using atorvastatin-based preventive therapy]. , 2008, Revista espanola de cardiologia.

[96]  M. Trip,et al.  P Lipid Reduction in Adolescents Efficacy and Safety of Coadministration of Ezetimibe and Simvastatin in Adolescents With Heterozygous Familial Hypercholesterolemia , 2008 .

[97]  P. Macfarlane,et al.  Long-term follow-up of the West of Scotland Coronary Prevention Study. , 2007, The New England journal of medicine.

[98]  J. Kastelein,et al.  Statin Treatment in Children With Familial Hypercholesterolemia: The Younger, the Better , 2007, Circulation.

[99]  M. Trip,et al.  A Systematic Review and Meta-Analysis of Statin Therapy in Children With Familial Hypercholesterolemia , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[100]  Anita Špehar Uroić,et al.  [Three-year-old boy--a homozygote for familiar hypercholesterolemia]. , 2007, Lijecnicki vjesnik.

[101]  S. Tonstad,et al.  Marked changes in plasma lipids and lipoproteins during pregnancy in women with familial hypercholesterolemia. , 2006, Atherosclerosis.

[102]  J. Kastelein,et al.  Premature cardiovascular disease in young women with heterozygous familial hypercholesterolemia , 2006, Expert review of cardiovascular therapy.

[103]  M. Trip,et al.  Plant stanols do not restore endothelial function in pre-pubertal children with familial hypercholesterolemia despite reduction of low-density lipoprotein cholesterol levels. , 2006, The Journal of pediatrics.

[104]  Zahi A Fayad,et al.  Risk scores predict atherosclerotic lesions in young people. , 2005, Archives of internal medicine.

[105]  M. Malloy,et al.  Effect of docosahexaenoic acid on lipoprotein subclasses in hyperlipidemic children (the EARLY study). , 2005, The American journal of cardiology.

[106]  S. Ho,et al.  Meta-analysis of the effects of soy protein containing isoflavones on the lipid profile. , 2005, The American journal of clinical nutrition.

[107]  J. Keaney,et al.  Role of oxidative modifications in atherosclerosis. , 2004, Physiological reviews.

[108]  M. Malloy,et al.  Docosahexaenoic acid supplementation alters plasma phospholipid fatty acid composition in hyperlipidemic children: Results from the Endothelial Assessment of Risk from Lipids in Youth (EARLY) study , 2004 .

[109]  H. Büller,et al.  Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study , 2004, JAMA.

[110]  J. Kastelein,et al.  Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands. , 2004, Seminars in vascular medicine.

[111]  E. Stroes,et al.  Plant sterols lower LDL cholesterol without improving endothelial function in prepubertal children with familial hypercholesterolaemia , 2003, Journal of Inherited Metabolic Disease.

[112]  Jonathan D. Cohen,et al.  Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. , 2003, The Journal of clinical investigation.

[113]  E. Sijbrands,et al.  Family History and Cardiovascular Risk in Familial Hypercholesterolemia: Data in More Than 1000 Children , 2003, Circulation.

[114]  J. Kastelein,et al.  Early statin therapy restores endothelial function in children with familial hypercholesterolemia. , 2002, Journal of the American College of Cardiology.

[115]  L. Ose,et al.  Plant sterol ester-enriched spread lowers plasma total and LDL cholesterol in children with familial hypercholesterolemia. , 2002, The American journal of clinical nutrition.

[116]  Margaret Thorogood,et al.  Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia , 2002, BMJ : British Medical Journal.

[117]  K. Widhalm,et al.  Effect of a Rapeseed Oil Substituting Diet on Serum Lipids and Lipoproteins in Children and Adolescents with Familial Hypercholesterolemia , 2002, Journal of the American College of Nutrition.

[118]  F. van Leuven,et al.  Impact of genetic defects on atherosclerosis in patients suspected of familial hypercholesterolaemia , 2001, European journal of clinical investigation.

[119]  B. Kirkhus,et al.  Serum cholesterol predictive equations with special emphasis on Trans and saturated fatty acids. An analysis from designed controlled studies , 2001, Lipids.

[120]  S. Gidding,et al.  Usefulness of electron beam tomography in adolescents and young adults with heterozygous familial hypercholesterolemia. , 1998, Circulation.

[121]  B. McCrindle,et al.  Garlic extract therapy in children with hypercholesterolemia. , 1998, Archives of pediatrics & adolescent medicine.

[122]  R. Tracy,et al.  Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. , 1998, The New England journal of medicine.

[123]  J L Witztum,et al.  Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. , 1997, The Journal of clinical investigation.

[124]  M. Davidson,et al.  A psyllium-enriched cereal for the treatment of hypercholesterolemia in children: a controlled, double-blind, crossover study. , 1996, The American journal of clinical nutrition.

[125]  J. Hoeg,et al.  Detection and quantitation of calcific atherosclerosis by ultrafast computed tomography in children and young adults with homozygous familial hypercholesterolemia. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[126]  D. Betteridge,et al.  Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level. , 1994, The Journal of clinical investigation.

[127]  K. Widhalm,et al.  Effect of soy protein diet versus standard low fat, low cholesterol diet on lipid and lipoprotein levels in children with familial or polygenic hypercholesterolemia. , 1993, The Journal of pediatrics.

[128]  D. Genser,et al.  INCREASED LIPOPROTEIN(a) LEVELS IN CHILDREN WITH FAMILIAL HYPERCHOLESTEROLAEMIA , 1988, The Lancet.

[129]  M. Brown,et al.  A receptor-mediated pathway for cholesterol homeostasis. , 1986, Science.

[130]  D. Bilheimer,et al.  Cellular pathology of homozygous familial hypercholesterolemia. , 1979, The American journal of pathology.

[131]  J. Verter,et al.  Coronary Artery Disease in 116 Kindred with Familial Type II Hyperlipoproteinemia , 1974, Circulation.

[132]  Ja Wilson,et al.  Principles and practice of screening for disease , 1968 .